Last reviewed · How we verify
NCT05916690
Electrochemotherapy for the Treatment of Vulvar Cancer
NA trial testing Electrochemotherapy with bleomycin or cisplatin in Vulvar Cancer in 20 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Institute of Oncology Ljubljana |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 March 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Slovenia |
Drugs / interventions tested
- Electrochemotherapy with bleomycin or cisplatin — full drug profile →
Conditions studied
- Vulvar Cancer — all drugs for Vulvar Cancer →
Sponsor
Institute of Oncology Ljubljana
Who can join
18 and older, any sex, with Vulvar Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Electrochemotherapy is a local treatment modality with effectiveness comparable to other local ablation techniques. With electrochemotherapy 80% objective response can be achieved and is suitable for the treatment of different types of tumors. The method is based on increased drug delivery to cells previously exposed to electroporation. The most commonly used cytotoxic agents are bleomycin and cisplatin. The aim of the proposed clinical trial is to determine the efficacy, feasibility and safety of electrochemotherapy in the treatment of vulvar cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Treatment of vulvar cancer recurrence with electrochemotherapy: a case-control study.
Vivod G, Omerzel M, Kovacevic N, Gasljevic G, et al · · 2024 · cited 1× · PMID 38770722 · DOI 10.2340/1651-226x.2024.33241 -
Quality of life of women with recurrent vulvar cancer treated with electrochemotherapy.
Vivod G, Cilensek I, Kovacevic N, Sersa G, et al · · 2025 · PMID 40105247 · DOI 10.2478/raon-2025-0019
Verify or expand the search:
- PubMed search for NCT05916690
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Electrochemotherapy with bleomycin or cisplatin
Trials testing the same drug.
- NCT04760327 — Electrochemotherapy of Gynecological Cancers · Phase 2 · recruiting
Other recruiting trials for Vulvar Cancer
Currently open trials in the same condition.
- NCT07124000 — DESTINY-PANTUMOUR04 · recruiting
- NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
- NCT06677190 — Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin · Phase 2 · recruiting
- NCT05576831 — STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision · NA · recruiting
- NCT06495554 — Danish Vulva Cancer Recurrence Study · NA · recruiting
Other Institute of Oncology Ljubljana trials
Trials by the same sponsor.
- NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
- NCT07432399 — Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study) · Phase 2 · recruiting
- NCT06650423 — Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer · recruiting
- NCT07420647 — Pilot Study of Individualized Treatment for Genitourinary Syndrome of Menopause in Women After Cancer Treatment · NA · active not recruiting
- NCT07416500 — BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05916690 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Oncology Ljubljana
- Last refreshed: 19 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05916690.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing